<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33531">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995019</url>
  </required_header>
  <id_info>
    <org_study_id>Artralgia1</org_study_id>
    <secondary_id>2013-003365-34</secondary_id>
    <nct_id>NCT01995019</nct_id>
  </id_info>
  <brief_title>Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone</brief_title>
  <official_title>PhaseIV Study of Intra-articular Methylprednisolone in TMJ Arthralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that a single dose intra-articular injection of corticosteroids are
      effective in  relieving temporomandibular arthralgia pain.

      The purpose of the study is therefore to evaluate the effect of a single dose
      intra-articular methylprednisolone  vs. placebo in a month perspective on subjects with
      unilateral arthralgia of the TMJ.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized blinded multicenter controlled study on 64 subjects (18 years or older)
      with the  diagnosis of unilateral arthralgia of the TMJ.

      The subject visit the clinic at three occasions; one enrollment visit, one baseline
      treatment visit and one evaluation visit one month after baseline.

      One week after baseline a follow-up telephone call is made with the purpose to track adverse
      events.

      Pain questionaries are completed morning, lunch and dinnertime during three days before
      treatment, five days after treatment and three days proceeding the evaluation visit.

      The study ís planned to commence 10th December 2013 and last patient out 15th January 2015.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>VAS pain score change at maximal mouth opening</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>100 mm analog Visual Analog Scale with endpoints &quot;No pain&quot; and &quot;Worst pain imaginable&quot; The intra-individual change of the VAS pain score between baseline and end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS pain score change at jaw rest</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>100 mm analog Visual Analog Scale with endpoints &quot;No pain&quot; and &quot;Worst pain imaginable&quot; The intra-individual change of the VAS pain score between baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrument measures</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>JFLS GCPS PHQ-9 PGIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Spontaneously reported by the subject or observed by the study staff from the baseline visit until the evaluation visit.
Reported by the subject in response to open questioning at visits/phone calls from the baseline visit until the evaluation visit &quot;Have you had any health problems since your last visit/contact?&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Arthralgia</condition>
  <condition>TMJ</condition>
  <arm_group>
    <arm_group_label>Physiologic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride 9 mg/ml liquid for parental use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depo-Medrol 40 mg/ml, single dose, injection, intra-articular</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>1 ml single dose Intra-articular Depo-Medrol 40 mg/ml</description>
    <arm_group_label>Physiologic saline</arm_group_label>
    <other_name>Depo-Medrol 40 mg/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline</intervention_name>
    <description>1 ml intra-articular placebo</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Sham substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or above

          -  the diagnosis arthralgia in one TMJ

          -  understands Swedish both verbally and in written

          -  signed informed concent

        Exclusion Criteria:

          -  TMJ sounds (clicking or crepitation)

          -  polyarthritis/connective tissue disease

          -  bilateral TMJ arthralgia

          -  fibromyalgia or other generalized pain

          -  ongoing infection

          -  ongoing dental treatment

          -  intra-articular corticosteroid injection of a TMJ the past 6 months

          -  previous surgery of the affected TMJ

          -  complex psychiatric/psychologic status

          -  institutionalized living including prisoners

          -  staff at the investigational clinic

          -  hypersensitive to local anesthetics

          -  hypersensitive to methylprednisolone

          -  hemophilia

          -  methemoglobinemia

          -  nursing

          -  compromized health status according to the judgment of the investigator

          -  concommitant use of the drugs cyclosporine, erytromycin, pentobarbital, itraconazole,
             ketoconazole, Rifampicin, Acetylsalicylic acid, Oral anticoagulant

          -  mentally retarded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Göran Isacsson, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orofacial pain unit, Västmanland Hospital Västerås</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Göran Isacsson, Ass prof,DDS</last_name>
    <phone>+46 2117 54 85</phone>
    <email>goran.isacsson@ltv.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orofacial pain unit, Malar Hospital Eskilstuna</name>
      <address>
        <city>Eskilstuna</city>
        <state>Södermanland</state>
        <zip>631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Adern, DDS</last_name>
      <phone>+46 16104651</phone>
      <email>bengt.adern@dll.se</email>
    </contact>
    <investigator>
      <last_name>Bengt Adern, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orofacial pain unit, Västmanland Hospital Västerås</name>
      <address>
        <city>Västerås</city>
        <state>Västmanland</state>
        <zip>72185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goran Isacsson, Assoc Prof</last_name>
      <phone>+4621175485</phone>
      <email>goran.isacsson@ltv.se</email>
    </contact>
    <investigator>
      <last_name>Göran Isacsson, DDS,ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orofacial pain unit Eastman Institute</name>
      <address>
        <city>Stockholm</city>
        <zip>113 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Britt Hedenberg-Magnusson, DDS, dr med</last_name>
      <phone>+468-7298983</phone>
      <email>britt.hedenberg-magnusson@ftv.sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orofacial pain unit, Dental Specialist Education Center</name>
      <address>
        <city>Örebro</city>
        <zip>70111</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Ström, DDS, ass prof</last_name>
      <phone>+4619-6024070</phone>
      <email>dan.strom@orebvroll.se</email>
    </contact>
    <investigator>
      <last_name>Dan Ström, DDS, ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthralgia</keyword>
  <keyword>Temporomandibular joint</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>injection</keyword>
  <keyword>intra-articular</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
